Medipattern Receives FDA Clearance For Visualize:Vascular(TM)
February 17 2011 - 12:00PM
Marketwired
Attention: Business/Financial Editors
The Medipattern Corporation ("Medipattern") (TSX VENTURE: MKI),
a pioneer in the development of medical imaging software solutions
that help medical practitioners to better understand lesions and
critical anatomy, is pleased to announce it has received U.S. Food
and Drug Administration (FDA) 510(k) clearance for its
Visualize:Vascular™ product. Visualize:Vascular is designed to
quantify image data; segmenting and measuring regions of interest
in vessels. Visualize can help a physician assess vascular disease
using ultrasound imaging readily available in most cardiology,
vascular radiology and vascular surgery practices today. The
product is now available for sale in the United States. First
shipments are anticipated in the second quarter of this calendar
year.
"Visualize:Vascular allows me to see the structure of the open
space in the artery, the residual lumen, which is available for
blood flow to the brain. This can be seen in both two and three
dimensions which enable us to pinpoint the exact area of critical
narrowing in the blood vessel. The beauty of this technology is
that it is totally non invasive and can serve as an adjunct to
standard duplex ultrasound. Traditionally, we use Doppler to
measure the velocities of blood flow in the vessel. From this data
we estimate the degree of narrowing to determine if there is
significant disease. Visualize affords us the ability to measure
the lumen directly. Clinically this is a tremendous asset for us
and will ultimately lead to improved patient care," commented
Francis J. Porreca, MD, FACS, RPVI, Director of Vascular Surgery,
Weiler Division of Montefiore, The University Hospital of the
Albert Einstein College of Medicine. "We have had the opportunity
to work with Medipattern over the past few years as they developed
Visualize. We have an ongoing data base that we are using to track
ultrasound and visualize images with the use of Visualize. I
believe Visualize has the potential to revolutionize the way we
look at ultrasound which will have a positive impact on patient
management. We look forward to clinical use where we can document
the value of this new and exciting technology."
"Visualize:Vascular brings a whole new look and feel to vascular
ultrasound: color 3D reconstruction of specific regions of interest
in vessels. Vascular ultrasound is one of the largest and higher
growth market segments for ultrasound imaging today. NAVIX
specializes in vascular laboratory services. We work closely with
vascular labs to increase use of quality standards and protocols,"
commented Robert Kane, Senior Vice President of Clinical Services,
Navix Diagnostix, Inc. "We saw that Medipattern's technology had
the power to let us see inside vessels in an ultrasound setting. We
became quite enthusiastic about the potential and joined
Medipattern in collecting data for them to develop Visualize.
Medipattern's imaging algorithm expertise; diligence and dedication
have enabled them to bring this product to market. The preliminary
response from the physicians that we regularly work with is very
enthusiastic and we are committed to seeing this product roll out
through our NAVIX sites and expect it to be received well by all
vascular labs, cardiology, radiology and surgical practices
performing vascular ultrasound."
"Visualize:Vascular is based on the Cadenza™ algorithm platform.
To create Visualize, we have both expanded our platform by
leveraging it from breast imaging to vascular imaging; and
simplified our platform from computer aided detection (CAD) as we
do in breast imaging to 3D reconstruction of segmented regions of
interest. This allows us to focus on visualization which enables
our customers to get a better mental picture of the subject and
from this make a detailed analysis," commented Jeff Collins,
President and CEO of The Medipattern Corporation. "We wish to thank
all of our data collection partners. Their belief in us and
direction has been inspirational to us. Visualize:Vascular will be
deployed through our data collection sites in a limited roll out
followed by sales to key partners and then released for general
sales. First shipments are expected next quarter."
About The Medipattern Corporation:
Medipattern® is a pioneer in the development of imaging software
solutions that help medical practitioners to better understand
lesions and critical anatomy. Our first-to-market, award-winning
B-CAD® advances breast ultrasound computer aided detection (CAD) by
streamlining workflow and organizing information into a
comprehensive patient record. Medipattern uses its Cadenza™ CAD
Technology to power the digital conversion in medical
communications. B-CAD automatically creates fully digital
standardized worksheets and reports that make every practice more
efficient, productive and ultimately more effective. For more
information, please visit the Company's website at:
www.medipattern.com.
B-CAD® and Medipattern® are a registered mark of The Medipattern
Corporation.
Forward-looking statements
This document contains forward-looking statements relating to
Medipattern's performance, operations, or business environment.
These statements are based on what we believe are reasonable
assumptions given currently available information and our
understanding of Medipattern's current activities. We have tried,
whenever possible, to identify these forward-looking statements
using words such as "anticipates," "believes," "estimates,"
"expects," "plans," "intends," "potential", and similar
expressions. Forward-looking statements are not guarantees of
future performance and involve risks and uncertainties that are
difficult to predict or control. A number of factors could cause
actual outcomes and results to differ materially from those
expressed in forward-looking statements. These factors include but
are not limited to those set forth in the Company's corporate
filings, (posted at www.sedar.com). In addition, these
forward-looking statements relate to the date on which they are
made. The Company disclaims any intention or obligation to update
or revise any forward-looking statements for any reason. Readers
should not rely on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: The Medipattern Corporation Jeff Collins CEO (416)
744-0009 ext. 224 jcollins@medipattern.com www.medipattern.com
Spinnaker Capital Markets Inc. Kevin O'Connor (416) 962-3300 ext.
226 ko@spinnakercmi.com
The Medipattern Corp. (TSXV:MKI)
Historical Stock Chart
From Jun 2024 to Jul 2024
The Medipattern Corp. (TSXV:MKI)
Historical Stock Chart
From Jul 2023 to Jul 2024